MEPRON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
MEPRON by GSK is [see microbiology ()] . Approved for pneumocystis jirovecii pneumonia (pcp) in adults, adolescents (aged 13 years, older). First approved in 1992.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPRON is an oral small-molecule tablet approved in 1992 for treating Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 and older. The drug's mechanism of action is referenced in microbiology documentation but not detailed in available data. It represents a mature, established therapy in the opportunistic infection space.
$0.322MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal Part D volume signals a shrinking commercial team and reduced promotional investment.
Mechanism of Action
[see Microbiology ()] .
Worked on MEPRON at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.